INIS
biological markers
58%
biopsy
54%
blood
12%
brain
8%
cancer
12%
comparative evaluations
25%
concentration
25%
control
31%
data
61%
detection
70%
dna
8%
estradiol
5%
estrogens
50%
evaluation
55%
extraction
5%
failures
54%
genetics
20%
glioblastomas
100%
guidelines
11%
hazards
5%
histones
13%
hong kong
10%
hormones
10%
immunoassay
9%
laboratories
50%
liquids
54%
modifications
27%
monitoring
9%
mutations
50%
nucleosomes
58%
patients
22%
performance
10%
phenotype
10%
phospholipids
37%
populations
10%
pregnancy
10%
proteins
50%
reagents
50%
reduction
5%
reviews
68%
risks
70%
screening
25%
stratification
5%
testing
50%
therapy
8%
thrombin
44%
tissues
37%
tumor cells
8%
tumors
16%
women
5%
Keyphrases
Asundexian
50%
Cell Line Study
50%
Cervix Uteri
8%
Circulating Biomarkers
10%
Circulating nucleosomes
10%
Circulating Tumor Cells
10%
Circulating Tumor DNA (ctDNA)
10%
Citrullinated Histone H3
8%
Elevation Control
8%
Epigenetic Profile
8%
Exogenous Hormone Use
16%
EZH2 Inhibitor
8%
Factor V Leiden mutation
33%
Genetic Testing
16%
Glioma Diagnosis
10%
H3S10ph
8%
HMC3
8%
Inherited Condition
16%
Leiden mutation
16%
Liquid Biopsy
50%
Literature Review Analysis
50%
Relapse Detection
8%
Solid Cancer
8%
Volition
8%
Women's Time
6%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
50%
Blood Clotting Factor 8
12%
Brain Tumor
8%
Calcium Ion
16%
Circulating Tumor DNA
8%
Clinical Study
6%
Diethylstilbestrol
6%
Estrogen Derivative
12%
Ethinylestradiol
18%
F Factor
12%
Levonorgestrel
6%
Oral Contraceptive Agent
50%
Pharmacodynamics
50%
Phospholipid
50%
Progestin
6%
Random Effects Model
6%
Thrombin
5%
Thromboplastin
50%
Venous Thromboembolism
50%
